225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Executes the first project for developing and manufacturing a novel anticancer mAb
To accelerate the development of next-generation radioconjugates to treat cancer
Sen spent a decade with Biocon and held various key roles,
Acquisition of exclusive commercialization rights for European markets
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
